132 related articles for article (PubMed ID: 36228576)
1. Effects of Androgen Deprivation Therapy on Extraocular Muscles, Retrobulbar Orbital Fat, and the Optic Nerve in Patients with Prostate Cancer.
Sonmez HK; Sonmez G; Dogan S; Horozoglu F; Demirtas A; Evereklioglu C
Ophthalmic Res; 2023; 66(1):272-280. PubMed ID: 36228576
[TBL] [Abstract][Full Text] [Related]
2. [MRI study of the thickness and width of the extraocular muscles in normal subjects].
Li R; Xia S; Wang J; Sun F; Qi J
Zhonghua Yan Ke Za Zhi; 2015 Jun; 51(6):434-8. PubMed ID: 26310117
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
Boxer RS; Kenny AM; Dowsett R; Taxel P
Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer.
Mitsuzuka K; Kyan A; Sato T; Orikasa K; Miyazato M; Aoki H; Kakoi N; Narita S; Koie T; Namima T; Toyoda S; Fukushi Y; Habuchi T; Ohyama C; Arai Y; ;
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):57-62. PubMed ID: 26503109
[TBL] [Abstract][Full Text] [Related]
8. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
9. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
10. Effects of various extraocular muscle enlargement patterns on muscle diameter index in graves ophthalmopathy patients: a retrospective cohort study.
Yang J; Chen J; Shi B; You Y; Pi X; Zhao G; Jiang F
Sci Rep; 2023 Oct; 13(1):16939. PubMed ID: 37805656
[TBL] [Abstract][Full Text] [Related]
11. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
12. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
13. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.
Morote J; Esquena S; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX; Planas J; Catalán R; Reventós J
Anticancer Drugs; 2005 Sep; 16(8):863-6. PubMed ID: 16096434
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
15. Normative measurements of extraocular musculature by multislice computed tomography.
Zhang ZH; Chen Y; Wang Y; Meng W; Fang HY; Xu DD; Jin ZY
Chin Med Sci J; 2013 Jan; 27(4):232-6. PubMed ID: 23294589
[TBL] [Abstract][Full Text] [Related]
16. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.
Cerne JZ; McGuire SE; Grant SR; Munsell MF; Lee AK; Kudchadker RJ; Choi SL; Mahmood U; Hoffman KE; Pugh TJ; Frank SJ; Kuban DA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):346-51. PubMed ID: 23939133
[TBL] [Abstract][Full Text] [Related]
18. The effect of androgen deprivation therapy on
Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
[TBL] [Abstract][Full Text] [Related]
19. Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy.
Mustafa M; Rass HA; Yahya M; Hamdan K; Eiss Y
World J Surg Oncol; 2021 Jan; 19(1):5. PubMed ID: 33397422
[TBL] [Abstract][Full Text] [Related]
20. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
